{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$0.70 vs. cons $0.68",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue",
      "prediction": "MISS",
      "answer": "pred ~$14.2B vs. cons $14.4B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "COVID franchise revenue (Comirnaty + Paxlovid)",
      "prediction": "MISS",
      "answer": "pred ~$0.9B vs. cons $1.1B",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Revenue Guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$59.5-62.5B (midpoint $61.0B) vs. cons $61.0B (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY2026 Adjusted EPS Guidance",
      "prediction": "LOWER",
      "answer": "guide ~$2.80-3.00 (midpoint $2.90) vs. cons $2.96 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Cumulative LOE revenue impact through 2028 (post-Vyndamax settlement)",
      "prediction": "BETTER",
      "answer": "guide ~$14.5B vs. prior guide ~$17B (2026-2028 cumulative)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -1.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -2.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "An EPS beat is likely low-quality (cost controls/below-the-line) against a soft COVID-driven revenue miss, while FY26 guidance is only reaffirmed (not raised) for a third straight quarter, forcing sell-side to trim H2 COVID and top-line assumptions even after the headline beat. With no fresh catalyst to counter the SigVie-002 oncology overhang, HSBC-style caution, and a lame-duck CFO on the call, negative revisions to out-period numbers likely compound the initial reaction rather than reverse it, pulling the stock lower over the following days before dividend yield/valuation support limits further downside.",
  "day5_confidence": "MEDIUM"
}